Biologic advantage won’t come from better biology alone, but from delivery technology and designing the full experience around patients, providers, and supply chains.
- From IV To Subcutaneous: It's Not About Convenience, It's About System Design
- Beyond Biologics: A Biophysical Approach To Crohn's Disease
- 6 Packaging And Delivery Challenges For Biologic Therapies
- Does TSLP Inhibition Signal The Next Wave Of Respiratory Biologics?
- Nanosystems And Rare Diseases: Opportunities And Limitations
- 3 Emerging Trends In Drug Delivery Device Pipelines
- Organic Impurities: New Draft ICH Q3E Guidance For Leachables And Extractables
- Closing The Adherence Gap: The Connected Health Era
ON-DEMAND WEBINARS
What technical issues need to be addressed if an API is to be successfully micronized? Explore a robust process development strategy that ensures all attributes critical for quality are maintained.
Explore some of the more challenging aspects surrounding in-use testing for parenteral delivery along with potential strategies to address these issues.
Spray drying offers a solution to formulation challenges for enhancing the bioavailability of poorly soluble APIs but requires technical capability and operational excellence to accomplish the process successfully.
See how an amorphous solid dispersion (ASD) of acalabrutinib was designed using in vitro studies and in silico modeling. Understand how ASD formulations can enhance bioavailability.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![West3]( "Taking A Best Practice Approach To Contamination Control")
Taking A Best Practice Approach To Contamination ControlImplementing the EU GMP Annex 1 requires a holistic, evolutionary Contamination Control Strategy built on standardization, data analytics, and continuous improvement for a zero-defect mindset.
-
![Self injection med device GettyImages-1322057207]( "Overcoming Wet Injection Challenges With Human-Centric Design")
Overcoming Wet Injection Challenges With Human-Centric DesignBy understanding the causes of wet injections and employing effective mitigation strategies, we can design safer, more user-friendly, and more effective devices.
-
![Doctor-patient-GettyImages-1345513639]( "Evolution Of Novel Polymers To Overcome Limits In Sustained Drug Delivery")
Evolution Of Novel Polymers To Overcome Limits In Sustained Drug DeliveryDegradable polymers evolved from aliphatic polyesters to nitrogen-bearing biomaterials such as polyurethanes and polyester amides. Explore a brief history of the development of PEA polymers.
-
![Autoinjector-Insulin-Pen-Delivery-Device-GettyImages- 1086688132]( "Is The Autoinjector Dead? The Future Of Patient-Centered Drug Delivery")
Is The Autoinjector Dead? The Future Of Patient-Centered Drug DeliveryAutoinjectors revolutionized drug delivery, but innovation is shifting toward oral, wearable, and alternative platforms. Future focus emphasizes patient experience, sustainability, and broader drug delivery toolkits beyond the autoinjector.
-
![GettyImages-1185624320-scientist-lab-smiling]( "Selecting A CDMO For Custom Activated PEGs")
Selecting A CDMO For Custom Activated PEGsCustom-activated PEGs require thoughtful planning and precise analytical control. Discover key considerations for selecting a partner capable of supporting scalable, compliant PEGylation.
-
![iStock-1319077865-lab-team-computer-research]( "Selecting Drug Delivery Systems For Higher Doses, Viscosities And Lower Risk")
Selecting Drug Delivery Systems For Higher Doses, Viscosities And Lower RiskDiscover how companies can de-risk their device selection as they bring this new generation of high-volume, high-viscosity biologics to market.
-
![GettyImages-1398310603-Ophthalmology_Exam_Eye]( "New Polymer Overcomes Limits In Sustained Drug Delivery In Ophthalmology")
New Polymer Overcomes Limits In Sustained Drug Delivery In OphthalmologyChallenges specific to eye physiology complicate the development of new therapies and necessitate innovative drug delivery methods. Biodegradable polymers show promise in addressing these challenges.
-
![Patent Trolls]( "The Largest LOE Event In US Pharma History")
The Largest LOE Event In US Pharma HistoryAhead of the first biosimilar Humira product set to launch in 365 days, this article provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.
-
![GettyImages-1066989062-gene-cell-doctor-research]( "Vial Adapter Transfer Device Compatibility With Cell Therapies")
Vial Adapter Transfer Device Compatibility With Cell TherapiesNeedles and syringes are commonly used to retrieve cell therapies from vials, posing the risk of needle stick injury. Explore the suitability of needle-free polycarbonate transfer devices.
-
![adare osd]( "Combining Powdose® And Diffucaps® For Precise Solid Oral Dosing")
Combining Powdose® And Diffucaps® For Precise Solid Oral DosingCombining POWDOSE® and Diffucaps® enables precise, individualized solid oral dosing—improving drug delivery, patient compliance, and therapeutic outcomes in personalized medicine applications.
TOM'S TAKES ON DRUG DELIVERY
TALKING WITH TOM VIDEOCASTS
Fran offers keen industry and technical insights exclusively on Drug Delivery Leader.
DELIVERED BY DEGRAZIO
-
![Delivered _by _DeGrazio_Logo_Color_2]( "6 Packaging And Delivery Challenges For Biologic Therapies")
6 Packaging And Delivery Challenges For Biologic TherapiesIn this article, Fran DeGrazio identifies six aspects of biologics-based therapy packaging and delivery that, if addressed, may help to ensure successful product development and lifecycle management. They include 1) chemical compatibility with device functionality, 2) long-acting formulations, 3) product stability, 4) primary packaging and device integration, 5) cold storage, and 6) higher concentrations and viscosities.
FREE EBOOK: COMBINATION PRODUCTS
Combination products provide significant avenues for increasing patient adherence and overall efficacy. This collection outlines the opportunity and identifies strategies for gaining regulatory approval.
